As of today (2024-04-30), Medicure's share price is C$1.07.
Medicure's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.09. Hence, Medicure's Price-to-Free-Cash-Flow Ratio for today is 11.76.
The historical rank and industry rank for Medicure's Price-to-Free-Cash-Flow or its related term are showing as below:
TSXV:MPH'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.03 Med: 22.09 Max: 650
Current: 11.76
During the past 13 years, Medicure's highest Price-to-Free-Cash-Flow Ratio was 650.00. The lowest was 2.03. And the median was 22.09.
TSXV:MPH's Price-to-Free-Cash-Flow is ranked better than 74.7% of 494
companies
in the Drug Manufacturers industry
Industry Median: 22.58
vs TSXV:MPH: 11.76
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Medicure was 19.30% per year.
During the past 13 years, Medicure's highest 3-Year average Free Cash Flow per Share Growth Rate was 401.60% per year. The lowest was -106.50% per year. And the median was -6.10% per year.
Medicure Price-to-Free-Cash-Flow Historical Data
The historical data trend for Medicure's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medicure's Price-to-Free-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Medicure's Price-to-Free-Cash-Flow falls into.
Medicure Price-to-Free-Cash-Flow Calculation
Medicure's Price-to-Free-Cash-Flow ratio for today is calculated as
Medicure's Share Price of today is C$1.07. Medicure's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Medicure Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Medicure's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Medicure Inc is a biopharmaceutical company. It is involved in the research, clinical development, and commercialization of human therapeutics for the United States hospital market. Further, it also operates a specialty pharmacy in the United States of America. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:MPH has been successfully added to your 